Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013)

Abstract

Purpose: Official guideline published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). Hypertensive pregnancy disorders contribute significantly to perinatal as well as maternal morbidity and mortality worldwide. Also in Germany these diseases are a major course for hospitalization during pregnancy, iatrogenic preterm birth and long-term cardiovascular morbidity. Methods: This S1-guideline is the work of an interdisciplinary group of experts from a range of different professions who were commissioned by DGGG to carry out a systematic literature search of positioning injuries. Members of the participating scientific societies develop a consensus in an informal procedure. Afterwards the directorate of the scientific society approves the consensus. Recommendations: This guideline summarizes the state-of-art for classification, risk stratification, diagnostic, treatment of hypertensive pregnancy disorders.

Zusammenfassung

Ziel: Offizielle Leitlinie, publiziert und koordiniert von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Hypertensive Schwangerschaftserkrankungen verursachen weltweit einen hohen Anteil an der neonatalen und mütterlichen Morbidität und Mortalität. Auch in Deutschland tragen sie wesentlich zu Krankenhauseinweisungen während der Schwangerschaft, iatrogener Frühgeburtlichkeit und kardiovaskulärer Langzeitmorbidität bei. Methoden: Mitglieder der beteiligten Fachgesellschaften entwickeln in einem informellen Prozess einen Konsensus. Anschließend bestätigen die Direktorien der Fachgesellschaften diesen Konsensus. Empfehlungen: In der Leitlinie wird der aktuelle Standard für die Benennung, Früherkennung, Diagnostik, Behandlung und Nachsorge hypertensiver Schwangerschaftserkrankungen gegeben.

Key words

preeclampsia - hypertension - HELLP syndrome

Schlüsselwörter

Präeklampsie - Hypertonie - HELLP–Syndrom

• References

• 1 Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol 2013; 25: 124-132
• 2 Schutte JM, Schuitemaker NW, van Roosmalen J. Dutch Maternal Mortality Committee. Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG 2008; 115: 732-736
• 3 Center for Maternal and Child Enquiries (CMACE). Saving Mothersʼ Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl. 01) 1-203
• 4 Kuc S, Wortelboer EJ, van Rijn BB et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 2011; 66: 225-239
• 5 Akolekar R, Syngelaki A, Poon L et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15
• 6 Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22
• 7 Brown MA, Lindheimer MD, de Swiet M et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV
• 8 ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet 2002; 77: 67-75 Online: http://mail.ny.acog.org/website/SMIPodcast/DiagnosisMgt.pdf last access: 01.12.2013
• 9 Lowe SA, Brown MA, Dekker G et al. Society of Obstetric Medicine of Australia and New Zealand. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 2009; 49: 242-246
• 10 Turner JA. Diagnosis and management of pre-eclampsia: an update. Int J Womens Health 2010; 2: 327-337
• 11 National Collaborating Centre for Womenʼs and Childrenʼs Health – Commissioned by the National Institute for Health and Clinical Excellence, Royal College of Obstetricians and Gynaecologists. Hypertension in pregnancy. 2011.. Online: http://www.nice.org.uk/nicemedia/live/13098/50475/50475.pdf last access: 01.12.2013
• 12 Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension?. Am J Obstet Gynecol 2012; 207: 214.e1-214.e6
• 13 James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placenta, immune and cardiovascular pieces. J Pathol 2010; 221: 363-378
• 14 Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 2011; 66: 497-506
• 15 Tranquilli AL, Brown MA, Zeeman GG et al. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens 2013; 3: 44-47
• 16 Douglas KA, Redman KA. Eclampsia in the United Kingdom. BMJ 1994; 309: 1395-1400
• 17 Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000; 182: 307-312
• 18 Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007; 114: 1072-1077
• 19 Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103: 981-991
• 20 Seely EW, Ecker J. Chronic hypertension in pregnancy. N Engl J Med 2011; 365: 439-446
• 21 Conde-Agudelo A, Villar J, Lindheimer M. World Health Organisation systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391
• 22 Yu CK, Smith GC, Papageorghiou AT et al. An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193: 429-436
• 23 Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol 2007; 19: 103-109
• 24 Audibert F, Boucoiran I, An N et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 2010; 203: 383.e1-383.e8
• 25 Thilaganathan B, Wormald B, Zanardini C et al. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol 2010; 115: 1233-1238
• 26 Scazziocchio E, Figueras F. Contemporary prediction of preeclampsia. Curr Opin Obstet Gynecol 2011; 23: 65-71
• 27 Lachmann R, Schlembach D. Screening, Prädiktion und Prävention der Präeklampsie. Frauenarzt 2013; 4: 326-331
• 28 Akolekar R, Syngelaki A, Sarquis R et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74
• 29 Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30: 293-308
• 30 Carbillon L. First trimester uterine artery Doppler for the prediction of preeclampsia and foetal growth restriction. J Matern Fetal Neonatal Med 2012; 25: 877-883
• 31 Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C et al. EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-787
• 32 Mcelrath TF, Lim KH, Pare E et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207: 407.e1-407.e7
• 33 Melchiorre K, Wormald B, Leslie K et al. First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 133-137
• 34 Bahado-Singh RO, Jodicke C. Uterine artery Doppler in first-trimester pregnancy screening. Clin Obstet Gynecol 2010; 53: 879-887
• 35 Scazzocchio E, Figueras F, Crispi F et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013; 208: 203.e1-203.e10
• 36 Poon LC, Syngelaki A, Akolekar R et al. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fet Diagn Ther 2013; 13: 16-27
• 37 Myatt L, Clifton RG, Roberts JM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234-1242
• 38 Papageorghiou AT, Yu CK, Bindra R et al. Fetal Medicine Foundation Second Trimester Screening Group. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441-449
• 39 Cnossen JS, Morris RK, ter Riet G et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 701-711
• 40 Yu CK, Khouri O, Onwudiwe N et al. Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310-313
• 41 Phupong V, Dejthevaporn T. Predicting risks of preeclampsia and small for gestational age infant by uterine artery Doppler. Hypertens Pregnancy 2008; 27: 387-395
• 42 Cooper S, Johnson JA, Metcalfe A et al. The predictive value of 18–22 week uterine artery Doppler in patients with low first trimester maternal serum PAPP-A. Prenat Diagn 2009; 29: 248-252
• 43 Stepan H, Unversucht A, Wessel N et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-824
• 44 Spencer K, Yu CK, Savvidou M et al. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeksʼ gestation. Ultrasound Obstet Gynecol 2006; 27: 658-663
• 45 Gómez-Arriaga PI, Herraiz I, López-Jiménez EA et al. Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol 2013; 41: 530-537
• 46 Levine RJ, Lam C, Quian C et al. for the CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New Engl J Med 2006; 355: 992-1005
• 47 Crispi F, Domínguez C, Llurba E et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207
• 48 Crispi F, Llurba E, Domínguez C et al. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 31: 303-309
• 49 Verlohren S, Galindo A, Schlembach D et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-161.e11
• 50 Verlohren S, Herraiz I, Lapaire O et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-58.e8
• 51 Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1) 402-414
• 52 Roberge S, Villa P, Nicolaides K et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012; 31: 141-146
• 53 Bujold E, Morency AM, Roberge S et al. Acetylsalicylic acid for the prevention or preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynecol Can 2009; 31: 818-826
• 54 Murakami S, Saitoh M, Kubo T et al. Renal disease in women with severe preeclampsia or gestational proteinuria. Obstet Gynecol 2000; 96: 945-949
• 55 Stamilio DM, Sehdev HM, Morgan MA et al. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?. Am J Obstet Gynecol 2000; 182: 589-594
• 56 Dekker G, Sibai B. Primary, and tertiary prevention of preeclampsia. Lancet 2001; 357: 209-215
• 57 Julkunen H. Pregnancy and lupus nephritis. Scand J Urol Nephrol 2001; 35: 319-327
• 58 Erkan D, Sammaritano L. New insights into pregnancy-related complications in systemic lupus erythematosus. Curr Rheumatol Rev 2003; 5: 357-363
• 59 Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565
• 60 Chappell LC, Enye S, Seed P et al. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008; 51: 1002-1009
• 61 Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: risk factors and causal models. Best Pract Res Clin Obstet Gynaecol 2011; 25: 329-342
• 62 Pecks U, Maass N, Neulen J. Oocyte donation: a risk factor for pregnancy-induced hypertension: a meta-analysis and case series. Dtsch Arztebl Int 2011; 108: 23-31
• 63 Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Am J Obstet Gynceol 2008; 112 (2 Pt 1) 359-372
• 64 Brown MA, Mackenzie C, Dunsmuir W et al. Can we predict recurrence of pre-eclampsia or gestational hypertension?. BJOG 2007; 114: 984-993
• 65 Mostello D, Kallogjeri D, Tungsiripat R et al. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol 2008; 199: 55.e1-55.e7
• 66 Hernández-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009; 338: b2255
• 67 Leeners B, Neumaier-Wagner PM, Kuse S et al. Recurrence risk of hypertensive disease in pregnancy after HELLP syndrome. J Perinat Med 2011; 39: 673-678
• 68 Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005; 105: 402-410
• 69 Shennan A, Gupta M, Halligan A et al. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996; 347: 139-142
• 70 Brown MA, Buddle ML, Farrell T et al. Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. Lancet 1998; 352: 777-781
• 71 Bergert FW, Braun M, Clarius H et al. Hausärztliche Leitlinie Hypertonie – Therapie der Hypertonie. 2010.. Online: http://www.pmvforschungsgruppe.de/pdf/03_publikationen/hypertonie_ll.pdf last access: 01.12.2013
• 72 Pettit F, Brown MA. The management of pre-eclampsia: what we think we know. Eur J Obstet Gynecol Reprod Biol 2012; 160: 6-12
• 73 Brown MA, Mangos G, Davis G et al. The natural history of white coat hypertension during pregnancy. BJOG 2005; 112: 601-606
• 74 Villar J, Say L, Shennan A et al. Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and aclampsia. Int J Gynaecol Obstet 2004; 85 (Suppl. 01) S28-S41
• 75 Chung Y, de Greeff A, Shennan A. Validation and compliance of a home monitoring device in pregnancy: microlife WatchBP home. Hypertens Pregnancy 2009; 28: 348-359
• 76 Waugh JJ, Bell SC, Kilby MD et al. Optimal bedside urinanalysis for the detection of proteinuria in hypertensive pregnancy: a study of diagnostic accuracy. BJOG 2005; 112: 412-417
• 77 Gangaram R, Ojwang PJ, Moodley J et al. The accuracy of uterine dipsticks as a screening test for proteinuria in hypertensive disorders of pregnancy. Hypertens Pregnancy 2005; 24: 117-123
• 78 Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy. Obstet Gynecol 2010; 115: 365-375
• 79 Airoldi K, Weinstein L. Clinical significance of proteinuria in pregnancy. Obstet Gynecol Surv 2007; 62: 117-124
• 80 Côté AM, Brown MA, Lam E et al. Diagnostic accuracy of urinary spot protein : creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008; 336: 1003-1006
• 81 Yamasmit W, Chaithongwongwatthana S, Charoenvidhya D et al. Random urinary protein-to-creatinine ratio for prediction of significant proteinuria in women with preeclampsia. J Matern Fetal Neonatal Med 2004; 16: 275-279
• 82 Wiwanikit V. Periodic urinary protein creatinine ratio for predicting significant proteinuria in preeclampsia in different alternatives: time effectiveness analysis. Arch Gynecol Obstet 2010; 281: 571-573
• 83 Morris RK, Riley RD, Doug M et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012; 345: e4342
• 84 Chen BA, Parviainen K, Jeyabalan A. Correlation of catheterized and clean catch urine protein/creatinine ratios in preeclampsia evaluation. Obstet Gynecol 2008; 112: 606-610
• 85 Phelan LK, Brown MA, Davis GK et al. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. Hypertens Pregnancy 2004; 23: 135-142
• 86 Ochsenbein-Kölble N, Roos M, Gasser T et al. Cross-sectional study of weight gain and increase in BMI throughout pregnancy. Eur J Obstet Gynaecol Reprod Biol 2007; 130: 180-186
• 87 Thangaratinam S, Koopmans CM, Iyengar S et al. TIPPS (Test in Prediction of Preeclampsiaʼs Severity) Review Group. Accuracy of liver function test for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scan 2011; 90: 574-585
• 88 Ghosh SK, Raheja S, Tull A et al. Serum PlGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet 2012; 285: 417-422
• 89 Hawkins TL, Roberts JM, Mangos GJ et al. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. BJOG 2012; 119: 484-492
• 90 Sibiude J, Guibourdenche J, Dionne MD et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7: e50208
• 91 Rana S, Powe CE, Salahuddin S et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919
• 92 Milne F, Redman C, Walker J et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330: 576-580
• 93 Rath W. Hypertensive Schwangerschaftserkrankungen. Der Gynäkologe 1999; 32: 432-442
• 94 Thangaratinam S, Gallos ID, Meah N et al. TIPPS (Tests in Prediction of Pre-eclampsiaʼs Severity) Review Group. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis. 2011; 90: 564-573
• 95 Abalos E, Duley L, Steyn DW et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007; (1) CD002252
• 96 Redman CW, Roberts JM. Management of pre-eclampsia. Lancet 1993; 341: 1451-1454
• 97 Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257-265
• 98 Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 300-303
• 99 Altman D, Carroli D, Duley L et al. Magpie Trial Collaboration Group. Do women woth pre-eclampsia, an their babies, benefit from magnesium suplhate? The MagPie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-1890
• 100 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799
• 101 Steegers EA, van Dadelszen P, Duvekot JJ et al. Pre-eclampsia. Lancet 2010; 376: 631-644
• 102 Magee LA, Abalos E, von Dadelszen P et al. CHIPS Study Group. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol 2011; 72: 394-401
• 103 Schaefer C, Spielmann H, Vetter K. Arzneimittel in Schwangerschaft und Stillzeit. 8. Aufl.. München: Verlag Urban & Fischer; 2012
• 104 Committee on Obstetric Practice. Committe Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampisa. Obstet Gynecol 2011; 118: 1465-1468
• 105 Leveno KJ, Cunningham FG. Management of Preeclampsia. In: Lindheimer MD, Roberts JM, Cunningham FG, eds. Chesleyʼs hypertensive Disorders in Pregnancy. Stamford, Connecticut: Appleton & Lange; 1999: 543-580
• 106 Behandlung der hypertensiven Krise. Arznei-Telegramm 1999; 1: 2-5
• 107 Van den Born BJ, Beutler JJ, Gaillard CA et al. Dutch guideline for the management of hypertensive crisis – 2010 revision. Neth J Med 2011; 69: 248-255
• 108 Wacker JR, Wagner BK, Briese V et al. Antihypertensive therapy in patients with preeclampsia: a prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Med 2006; 127: 160-165
• 109 Carles G, Helou J, Dallah F et al. Use of injectable urapidil in pregnancy-induced hypertension and preeclampsia. J Gynecol Obstet Biol Reprod 2012; 41: 645-649
• 110 Magee LA, Cham C, Waterman EJ et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327: 955-960
• 111 Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; (3) CD001449
• 112 Duley L, Henderson-Smart DJ, Walker GJ et al. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2010; (12) CD000127
• 113 Duley L, Gülmezoglu AM, Henderson-Smart DJ et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010; (11) CD000025
• 114 Duley L, Henderson-Smart DJ, Chou D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2010; (10) CD000128
• 115 Duley L, Gülmezoglu AM, Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2010; (9) CD002960
• 116 Duley L. Pre-eclampsia, eclampsia, and hypertension. BMJ Clin Evid: 2011. 2011. pii 1402
• 117 Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG 2007; 114: 300-309
• 118 Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007; 114: 289-299
• 119 Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455-1463
• 120 Duley L, Matar HE, Almerie MQ et al. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010; (8) CD007388
• 121 Duley L, Williams J, Henderson-Smart DJ. Plasma volume expansion for treatment of women with pre-eclampsia. Cochrane Database Syst Rev 2000; (2) CD001805
• 122 Ganzevoort W, Rep A, Bonsel GJ et al. PETRA investigators. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 2005; 112: 1358-1368
• 123 Koopmans CM, Bijlenga D, Groen H et al. HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeksʼ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988
• 124 Alfirevic Z, Neilson JP. Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis. Am J Obstet Gynecol 1995; 172: 1379-1387
• 125 Westergaard HB, Langhoff-Roos J, Lingman G et al. A critical appraisal of the use of umbilical artery Doppler ultrasound in high-risk pregnancies: use of meta-analyses in evidence-based obstetrics. Ultrasound Obstet Gynecol 2001; 17: 466-476
• 126 Baschat AA. Pathophysiology of fetal growth restriction: implications for diagnosis and surveillance. Obstet Gynecol Surv 2004; 59: 617-627
• 127 Marsal K. Obstetric management of intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol 2009; 23: 857-870
• 128 Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high risk pregnancies. Cochrane Database Syst Rev 2010; (1) CD007529
• 129 Maulik D, Mundy D, Heitmann E et al. Evidence-based approach to umbilical artery Doppler fetal surveillance in high-risk pregnancies: an update. Clin Obstet Gynecol 2010; 53: 869-878
• 130 Galan HL. Timing delivery of the growth restricted fetus. Semin Perinatol 2011; 35: 262-269
• 131 Morris RK, Malin G, Robson SC et al. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 37: 135-142
• 132 Schlembach D. Intrauterine Wachstumsrestriktion – Diagnostik und Management. Geburtsh Frauenheilk 2012; 72: 373-375
• 133 Magann EF, Chauhan SP, Kinsella MJ et al. Antenatal testing among 1001 patients at high risk: the role of ultrasonographic estimate of amniotic fluid volume. Am J Obstet Gynecol 1999; 180: 1330-1336
• 134 Hashimoto K, Kasdaglis T, Jain S et al. Isolated low-normal amniotic fluid volume in the early third-trimester: association with adverse perinatal outcomes. J Perinat Med 2013; 41: 349-353
• 135 Backes CH, Marham K, Moorehead P et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy 2011; 2011: 2141365
• 136 Reddy UM, Bettegowda VR, Dias T et al. Term pregnancy: a period of heterogeneous risk for infant mortality. Obstet Gynecol 2011; 117: 1279-1287
• 137 Khashu M, Narayanan M, Bhargava S et al. Perinatal outcomes associated with preterm birth at 33 to 36 weekʼs gestation: a population-based cohort study. Pediatrics 2009; 123: 109-113
• 138 Simpson LL. Maternal medical disease: risk of antepartum fetal death. Semin Perinatol 2002; 26: 42-50
• 139 Odegård RA, Vatten LJ, Nilsen ST et al. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950-955
• 140 Odendaal HJ, Pattinson RC, Bam R et al. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeksʼ gestation: a randomized controlled trial. Obstet Gynecol 1990; 76: 1070-1075
• 141 Sibai BM, Mercer BM, Schiff E et al. Aggressive versus expectant management of severe pre-eclampsia at 28 to 32 weeksʼ gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171: 818-822
• 142 Haddad B, Deis S, Goffinet F et al. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeksʼ gestation. Am J Obstet Gynecol 2004; 190: 1590-1597
• 143 Visser W, Wallenburg HC. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 1995; 102: 111-117
• 144 Abramovici D, Friedman SA, Mercer BM et al. Neonatal outcome in severe preeclampsia at 24 to 36 weeksʼ gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter?. Am J Obstet Gynecol 1999; 180: 221-225
• 145 Shear RM, Rinfret D, Leduc L. Should we offer expectant management in cases of severe preterm preeclampsia with fetal growth restriction?. Am J Obstet Gynecol 2005; 192: 1119-1125
• 146 Sibai BM. Publications Committee, Society for Maternal-Fetal Medicine. Evaluation and management of severe preeclampsia before 34 weeksʼ gestation. Am J Obstet Gynecol 2011; 205: 191-198
• 147 Sibai BM, Akl S, Fairlie F et al. A protocol for managing severe preeclampsia in the second trimester. Am J Obstet Gynecol 1990; 163: 733-738
• 148 Gaugler-Senden IP, Huijssoon AG, Visser W et al. Maternal and perinatal outcome of preeclampsia with an onset before 24 weeksʼ gestation. Audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol 2006; 128: 216-221
• 149 Bombrys AE, Barton JR, Nowacki EA et al. Expectant management of severe preeclampsia at less than 27 weeksʼ gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008; 199: 247.e1-247.e6
• 150 Nassar AH, Adra AM, Chakhtoura N et al. Severe preeclampsia remote from term: labor induction or elective cesarean delivery?. Am J Obstet Gynecol 1998; 179: 1210-1213
• 151 Rath W. Hypertensive Schwangerschaftserkrankungen. In: Rath W, Friese K, Hrsg. Erkrankungen in der Schwangerschaft. Stuttgart, New York: Thieme; 2005: 73-97
• 152 Seal SL, Gosh D, Kamilya G et al. Does route of delivery affect maternal and perinatal outcome in women with eclampsia? A randomized controlled pilot study. Am J Obstet Gynecol 2012; 206: 484.e1-484.e7
• 153 Sibai BM, Ramadan MK, Usta I et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169: 1000-1006
• 154 Sanner B. Richtig Blutdruck messen. Druckpunkt 2008; 3: 14-17: Online: http://www.hochdruckliga.de/richtig-blutdruck-messen.html last access: 01.12.2013
• 155 Haller H. Leitlinien zur Diagnostik und Therapie der arteriellen Hypertonie. Druckpunkt 2007; 3: 16-18 http://www.hochdruckliga.de/leitlinien-zur-diagnostik-und-therapie-der-arteriellen-hypertonie.html last access: 01.12.2013
• 156 AWMF-Leitlinie 046/001: Leitlinien zur Behandlung der arteriellen Hypertonie.. Online: http://www.awmf.org/uploads/tx_szleitlinien/046-001_S2_Behandlung_der_arteriellen_Hypertonie_06-2008_06-2013.pdf last access: 01.12.2013
• 157 Leeners B, Rath W, Kuse S et al. Satisfaction with medical information in women with hypertensive disorders in pregnancy. J Psychosom Res 2006; 60: 39-44
• 158 Leeners B, Neumaier-Wagner P, Kuse S et al. Emotional stress and the risk to develop hypertensive diseases in pregnancy. Hypertens Pregnancy 2007; 26: 211-226
• 159 Sibai BM, Ramadan MK, Chari RS et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172 (1 Pt 1) 125-129
• 160 Nagai Y, Arai H, Washizawa Y et al. FSGS-like lesions in pre-eclampsia. Clin Nephrol 1991; 36: 134-140
• 161 Nisell H, Lintu H, Lunell NO et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995; 102: 876-881
• 162 Pourrat O, Pierre F. [Medical assessment after a pre-eclampsia: why? for whom? when? how? for what purpose?]. Rev Med Interne 2010; 31: 766-771
• 163 Spaan JJ, Ekhart T, Spaanderman ME et al. Renal function after preeclampsia: a longitudinal pilot study. Nephron Clin Pract 2012; 120: c156-c161
• 164 Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009; 9: 8
• 165 Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155: 1011-1016
• 166 Van Assche FA, Holemans K, Aerts L. Fetal growth and consequences for later life. J Perinat Med 1998; 26: 337-346
• 167 Irgens HU, Reisaeter L, Irgens LM et al. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001; 323: 1213-1217
• 168 Sattar N, Greer IA. Pregnancy complications and maternal cardiovascuar risk: opportunities for intervention and prevention. BMJ 2002; 325: 157-160
• 169 Wilson BJ, Watson MS, Prescott GJ et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326: 845-851
• 170 Roberts JM, Gammill H. Pre-eclampsia and cardiovascular disease in later life. Lancet 2005; 366: 961-962
• 171 Anderson CM. Preeclampsia: exposing future cardiovascular risk in mothers and their children. J Obstet Gynecol Neonatal Nurs 2007; 36: 3-8
• 172 Newstead J, von Dadelszen P, Magee LA. Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 283-294
• 173 Suzuki H, Watanabe Y, Arima H et al. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clin Exp Nephrol 2008; 12: 102-109
• 174 Lykke JA, Langhoff-Roos J, Sibai BM et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53: 944-951
• 175 Iversen L, Hannaford PC. Toxaemia of pregnancy and risk of mortality in later life: evidence from the Royal College of General Practitionersʼ Oral Contraception Study. Hypertens Pregnancy 2010; 29: 180-197
• 176 Lykke JA, Langhoff-Roos J, Lockwood CJ et al. Mortality of mothers from cardiovascular and non-cardiovascular causes following pregnancy complications in first delivery. Pediatr Perinat Epidemiol 2010; 24: 323-330
• 177 Díaz-Martínez LA, Día Pedraza Ndel M, Serrano Díaz NC et al. [The prognosis for children of mothers with preeclampsia. Part 2: long-term effects]. Arch Argent Pediatr 2011; 109: 519-524
• 178 Davis EF, Lazdam M, Lewandowksi AJ et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012; 129: e1552-e1561
• 179 Mangos GJ, Spaan JJ, Pirabhahar S et al. Markers of cardiovascular disease after hypertension in pregnancy. J Hypertens 2012; 30: 351-358
• 180 Smith GN, Pudwell J, Walker M et al. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can 2012; 34: 830-835
• 181 Brown MC, Best KE, Pearce MS et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013; 28: 1-19
• 182 Brown MC, Bell R, Collins C et al. Womenʼs perception of future risk following pregnancies complicated by preeclampsia. Hypertens Pregnancy 2013; 32: 60-73
• 183 Heidrich MB, Wenzel D, von Kaisenberg CS et al. Preeclampsia and long-term risk of cardiovascular disease: what do obstetrician-gynecologists know?. BMC Pregnancy Childbirth 2013; 13: 61
• 184 Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165 (5 Pt 1) 1408-1412
• 185 Dukler D, Porath A, Bashiri A et al. Remote prognosis of primiparous women with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001; 96: 69-74
• 186 Van Rijn BB, Hoeks LB, Bots ML et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195: 723-728
• 187 Langenveld J, Jansen S, van der Post J et al. Recurrence risk of a delivery before 34 weeks of pregnancy due to an early onset hypertensive disorder: a systemativ review. Am J Perinatol 2010; 27: 565-571
• 188 Langenveld J, Buttinger A, van der Post J et al. Recurrence risk and prediction of a delivery under 34 weeks of gestation after a history of a severe hypertensive disorder. BJOG 2011; 118: 589-595
• 189 Fischer T, Langenfeld M. Nachbetreuung von Präeklampsie-Patientinnen. In: Heilmann L, Rath W, Hrsg. Schwangerschaftshochdruck. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2002: 279-296
• 190 Fischer T, Pildner von Steinburg S, Diedrich F et al. Prävention der Präeklampsie. Zentralbl Gynakol 2005; 127: 83-90
• 191 Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynaecol 1982; 142: 159-167
• 192 Rath W, Loos W, Graeff H et al. Das HELLP-Syndrom. Der Gynäkologe 1992; 25: 430-440
• 193 Rath W, Faridi A, Dudenhausen JW. HELLP syndrome. J Perinat Med 2000; 28: 249-260
• 194 Marchand A, Galen RS, Van LF. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243: 1909-1911
• 195 Poldre PA. Haptoglobin helps diagnose the HELLP syndrome. Am J Obstet Gynecol 1987; 157: 1267
• 196 Wilke G, Rath W, Schutz E et al. Haptoglobin as a sensitive marker of hemolysis in HELLP syndrome. Int J Gynecol Obstet 1992; 39: 29-34
• 197 Van Runnard Heimel PJ, Franx A, Schobben AF et al. Corticosteroids, pregnancy, and HELLP syndrome: a review. Obstet Gynecol Surv 2005; 60: 57-70
• 198 Deruelle P, Coudoux E, Ego A et al. Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006; 125: 59-65
• 199 Van Runnard Heimel PJ, Kavelaars A, Heijnen CJ et al. HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. Hypertens Pregnancy 2008; 27: 253-265
• 200 Martin jr. JN, May WL, Magann EF et al. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Ostet Gynecol 1999; 180: 1407-1414
• 201 Hackenberg H, Rappe N, Wohlers S et al. Wertigkeit des C-reaktiven Proteins (CRP) beim HELLP-Syndrom. Geburtsh Frauenheilk 1998; 58: 508-512
• 202 Paternoster DM, Fantinato S, Stella A et al. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost 2006; 12: 330-337
• 203 Molvarec A, Prohászka Z, Nagy B et al. Association of increased serum heat shock protein 70 and C-reactive protein concentrations and decreased serum alpha(2)-HS glycoprotein concentration with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. J Reprod Immunol 2007; 73: 172-179
• 204 Pawelec M, Palczynski B, Karmowski A. HELLP syndrome in pregnancies below 26th week. J Matern Fetal Neonatal Med 2012; 25: 467-470
• 205 Reimer T, Rohrmann H, Stubert J et al. Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis. J Matern Fetal Neonatal Med 2013; 26: 263-269
• 206 Martin jr. JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006; 195: 914-934
• 207 Fischer T, Wildt L. Glukokortikoide und HELLP-Syndrom. Der Gynäkologe 1999; 32: 783-790
• 208 Rath W, Bartz C. Therapeutisches Vorgehen bei schwerer Präeklampsie und beim HELLP-Syndrom. Zentralbl Gynakol 2004; 126: 293-298
• 209 Gul A, Cebeci A, Aslan H et al. Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome. Gynecol Obstet Invest 2005; 59: 113-118
• 210 Bartz C, Rath W. Aktuelles Management beim HELLP-Syndrom. Gynäkol Gebursthilfliche Rundsch 2007; 47: 215-221
• 211 Magann EF, Bass D, Chauhan SP et al. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994; 171: 1148-1153
• 212 Van Pampus MG, Wolf H, Westenberg SM et al. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1998; 76: 31-36
• 213 Fischer T, Krause M, Beinder E et al. Schwangerschaftsverlängerung bei Patientinnen mit HELLP-Syndrom. Geburtsh Frauenheilk 1999; 59: 335-345
• 214 van Runnard Heimel PJ, Huisjes AJ, Franx A et al. A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. Eur J Obstet Gynecol Reprod Biol 2006; 128: 187-193
• 215 Beitins IZ, Bayard F, Ances IG et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81: 936-945
• 216 Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127: 264-267
• 217 Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975; 56: 1548-1554
• 218 OʼBrien JM, Miligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000; 183: 921-924
• 219 Magann EF, Perry jr. KG, Meydrech EF et al. Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994; 171: 1154-1158
• 220 Vigil-De Gracia P, García-Cáceres E. Dexamethasone in the post-partum treatment of HELLP syndrome. Int J Gynaecol Obstet 1997; 59: 217-221
• 221 Yalcin OT, Sener T, Hassa H et al. Effects of postpartum corticosteroids in patients with HELLP syndrome. Int J Gynaecol Obstet 1998; 61: 141-148
• 222 Martin jr. JN, Perry jr. KG, Blake PG et al. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynecol 1997; 177: 1011-1017
• 223 Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol 1999; 181: 304-309
• 224 OʼBrien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000; 183: 921-924
• 225 Schlembach D, Munz W, Fischer T. Effect of corticosteroids on HELLP syndrome: a case report. J Perinat Med 2000; 28: 502-505
• 226 Isler CM, Barrilleaux PS, Magann EF et al. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001; 184: 1332-1337
• 227 Mecacci F, Carignani L, Cioni R et al. Time course of recovery and complications of HELLP syndrome with two different treatments: heparin or dexamethasone. Thromb Res 2001; 102: 99-105
• 228 Varol F, Aydin T, Gucer F. HELLP syndrome and postpartum corticosteroids. Int J Gynaecol Obstet 2001; 73: 157-159
• 229 OʼBrien JM, Shumate SA, Satchwell SL et al. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am J Obstet Gynecol 2002; 186: 475-479
• 230 Crane JM, Tabarsi B, Hutchens D. The maternal benefits of corticosteroids with HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. J Obstet Gynaecol Can 2003; 25: 650-655
• 231 Isler CM, Magann EF, Rinehart BK et al. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Int J Gynaecol Obstet 2003; 80: 291-297
• 232 Martin jr. JN, Thigpen BD, Rose CH et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003; 189: 830-834
• 233 Fonseca JE, Méndez F, Cataño C et al. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005; 193: 1591-1598
• 234 Woudstra DM, Chandra S, Hofmeyr GJ et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010; (9) CD008148
• 235 Sullivan CA, Magann EF, Perry jr. KG et al. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994; 171: 940-943
• 236 Van Pamus MG, Wolf H, Mayruhu G et al. Long-term follow-up in patients with a history of (H)ELLP syndrome. Hypertens Pregnancy 2001; 20: 15-23